Top FDA official sees more vaccine scrutiny in Trump's presidency
Nov 21 (Reuters) - The U.S. Food and Drug Administration is likely to come under tighter scrutiny over vaccine development and safety testing once Donald Trump takes over as the country's president, a top official at the agency said on Thursday.
Peter Marks, director of the FDA's Center for Biologics Evaluation and Research, said at an industry conference that the agency could be asked to be more transparent and meet more often with outside advisers to discuss vaccines.
"I don't necessarily view that as a bad thing," he said at the conference hosted by brokerage Jefferies. "That may turn out to be an opportunity to have an open dialogue."
Marks said the FDA could also shift its messaging on vaccines by emphasizing that the benefits of taking them outweigh the risks.
He said that outside of vaccines, he does not expect major changes in regulations of other biological drugs, including gene and cell therapies.
Industry insiders, biotech investors and Wall Street analysts are worried about potential regulatory changes for vaccines after Trump nominated Robert F. Kennedy Jr., an environmental activist who has spread misinformation on vaccines, to lead the Department of Health and Human Services.
The FDA and other health agencies like the Centers for Disease Control and Prevention fall under the purview of the HHS.
Shares of U.S. pharmaceutical companies, especially vaccine makers, fell on Friday on concerns over the changes Kennedy could make at the FDA, an agency he has accused of doing the bidding of Big Pharma and Big Food. His team has also said there would be a vetting process to find FDA employees with ties to the industry.
"There are things that could happen that could adversely affect the workforce," said Marks, adding that "it may get difficult to hire until a lot of the dust has settled".
Reporting by Leroy Leo and Mariam Sunny in Bengaluru; Editing by Anil D'Silva
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
